A CAR‑T therapy targeting Claudin18.2 has secured global regulatory approval. It is the first CAR‑T approved for a solid tumor.
규제 업데이트2026년 8월 30일•1분 읽기
Claudin18.2‑Targeted CAR‑T Therapy Achieves First Global Approval for Solid Tumor
Claudin18.2‑targeted CAR‑T therapy is the first CAR‑T to receive global approval for a solid tumor.
PharmaCountry 팀이 정리했습니다 · 출처: FiercePharma
평점
(0)
(0)
(0)
(0)
(0)
평가 남기기